evidence table

Glycine Memory Randomized Trial Evidence Table

Structured evidence table for Glycine Memory Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.

topicclaimevidence levelcitationsource
Glycine Memory Randomized Trial1 Aging is characterized by progressive physiological decline, including loss of skeletal muscle mass and function (Sarcopenia), reduced mitochondrial efficiency, and increased oxidative stress, all of which contribute to frailty and diminished quality of life in older adults ().3Wang Xiaolan (2026)Glycine and N-acetylcysteine supplementation, with or without exercise, in brain health and functional aging: implications for sarcopenia and frailty in older adults
Glycine Memory Randomized Trial1 2 3 4 5 By the age of 70, individuals may experience a 25%−30% reduction in muscle mass, which is strongly associated with impaired mobility, falls, and loss of independence ().3Wang Xiaolan (2026)Glycine and N-acetylcysteine supplementation, with or without exercise, in brain health and functional aging: implications for sarcopenia and frailty in older adults
Glycine Memory Randomized TrialLow circulating glycine levels have been associated with insulin resistance, obesity, and higher cardiometabolic risk (,).3Wang Xiaolan (2026)Glycine and N-acetylcysteine supplementation, with or without exercise, in brain health and functional aging: implications for sarcopenia and frailty in older adults
Glycine Memory Randomized TrialIn this review, the term “older adults” generally refers to individuals aged ≥60 or ≥65 years, consistent with definitions used by the World Health Organization and most geriatric clinical trials.3Wang Xiaolan (2026)Glycine and N-acetylcysteine supplementation, with or without exercise, in brain health and functional aging: implications for sarcopenia and frailty in older adults
Glycine Memory Randomized TrialIn bipolar disorder, for instance, combination treatment with lithium and valproate for mania prophylaxis is widely used in clinical practice, even though evidence for this and other maintenance polypharmacy lacks robust scientific backing [].4Franzen Avery D. (2026)Mechanism‐Based Polypharmacy as a Repurposing Strategy: The Case of D‐Cycloserine and Lurasidone
Glycine Memory Randomized TrialThe risks of polypharmacy are clear and well‐known to prescribers and researchers alike, but through intentional mechanistic pairings a rational way forward can be found.4Franzen Avery D. (2026)Mechanism‐Based Polypharmacy as a Repurposing Strategy: The Case of D‐Cycloserine and Lurasidone
Glycine Memory Randomized Trial6 Consequently, frameworks are required to distinguish between prescribing informed by empiric evidence or anecdotal experience and mechanistically informed combination therapies.4Franzen Avery D. (2026)Mechanism‐Based Polypharmacy as a Repurposing Strategy: The Case of D‐Cycloserine and Lurasidone
Glycine Memory Randomized Trial1 2 3 3 4 5 In modern psychiatry, polypharmacy, the concurrent administration of two or more psychotropic medications, has become increasingly common in clinical practice.4Franzen Avery D. (2026)Mechanism‐Based Polypharmacy as a Repurposing Strategy: The Case of D‐Cycloserine and Lurasidone
topicGlycine Memory Randomized Trial
claim1 Aging is characterized by progressive physiological decline, including loss of skeletal muscle mass and function (Sarcopenia), reduced mitochondrial efficiency, and increased oxidative stress, all of which contribute to frailty and diminished quality of life in older adults ().
evidence level3
citationWang Xiaolan (2026)
sourceGlycine and N-acetylcysteine supplementation, with or without exercise, in brain health and functional aging: implications for sarcopenia and frailty in older adults
topicGlycine Memory Randomized Trial
claim1 2 3 4 5 By the age of 70, individuals may experience a 25%−30% reduction in muscle mass, which is strongly associated with impaired mobility, falls, and loss of independence ().
evidence level3
citationWang Xiaolan (2026)
sourceGlycine and N-acetylcysteine supplementation, with or without exercise, in brain health and functional aging: implications for sarcopenia and frailty in older adults
topicGlycine Memory Randomized Trial
claimLow circulating glycine levels have been associated with insulin resistance, obesity, and higher cardiometabolic risk (,).
evidence level3
citationWang Xiaolan (2026)
sourceGlycine and N-acetylcysteine supplementation, with or without exercise, in brain health and functional aging: implications for sarcopenia and frailty in older adults
topicGlycine Memory Randomized Trial
claimIn this review, the term “older adults” generally refers to individuals aged ≥60 or ≥65 years, consistent with definitions used by the World Health Organization and most geriatric clinical trials.
evidence level3
citationWang Xiaolan (2026)
sourceGlycine and N-acetylcysteine supplementation, with or without exercise, in brain health and functional aging: implications for sarcopenia and frailty in older adults
topicGlycine Memory Randomized Trial
claimIn bipolar disorder, for instance, combination treatment with lithium and valproate for mania prophylaxis is widely used in clinical practice, even though evidence for this and other maintenance polypharmacy lacks robust scientific backing [].
evidence level4
citationFranzen Avery D. (2026)
sourceMechanism‐Based Polypharmacy as a Repurposing Strategy: The Case of D‐Cycloserine and Lurasidone
topicGlycine Memory Randomized Trial
claimThe risks of polypharmacy are clear and well‐known to prescribers and researchers alike, but through intentional mechanistic pairings a rational way forward can be found.
evidence level4
citationFranzen Avery D. (2026)
sourceMechanism‐Based Polypharmacy as a Repurposing Strategy: The Case of D‐Cycloserine and Lurasidone
topicGlycine Memory Randomized Trial
claim6 Consequently, frameworks are required to distinguish between prescribing informed by empiric evidence or anecdotal experience and mechanistically informed combination therapies.
evidence level4
citationFranzen Avery D. (2026)
sourceMechanism‐Based Polypharmacy as a Repurposing Strategy: The Case of D‐Cycloserine and Lurasidone
topicGlycine Memory Randomized Trial
claim1 2 3 3 4 5 In modern psychiatry, polypharmacy, the concurrent administration of two or more psychotropic medications, has become increasingly common in clinical practice.
evidence level4
citationFranzen Avery D. (2026)
sourceMechanism‐Based Polypharmacy as a Repurposing Strategy: The Case of D‐Cycloserine and Lurasidone

Learn next

Related evidence and supplement guides

SupplementGlycineNon-essential amino acid that cools core body temperature and deepens slow-wave sleep — remarkab...GuideGlycine Memory Randomized Trial: What the Evidence SaysGlycine Memory Randomized Trial has 2 source documents in the current Migaku evidence database....GuideGlycine Sleep Quality Randomized Trial: What the Evidence SaysGlycine Sleep Quality Randomized Trial has 2 source documents in the current Migaku evidence dat...GuideTaurine Memory Randomized Trial: What the Evidence SaysTaurine Memory Randomized Trial has 2 source documents in the current Migaku evidence database....GuideGlycine Cognition Randomized Trial: What the Evidence SaysGlycine Cognition Randomized Trial has 1 source documents in the current Migaku evidence databas...RankingBest Nootropics for Focus & Attention: 2026 Clinical Evidence ReviewWe separate the clinical evidence from the marketing hype, ranking the most effective brain supp...RankingBest Supplements for Anxiety: Evidence-Based Rankings 2026Anxiety supplements with genuine clinical evidence include ashwagandha (strongest for chronic an...RankingBest Nootropics for Focus & Cognition: 2026 Clinical RankingsAn examination of cognitive enhancers designed to increase neurotransmitter activity, improve sy...

Source documents

  1. Glycine and N-acetylcysteine supplementation, with or without exercise, in brain health and functional aging: implications for sarcopenia and frailty in older adults
  2. Mechanism‐Based Polypharmacy as a Repurposing Strategy: The Case of D‐Cycloserine and Lurasidone